← Back

Definitive Healthcare Corp

Definitive Healthcare Corp. provides a software-as-a-service (SaaS) healthcare commercial intelligence platform in the United States and internationally. The platform offers information on healthcare providers and their activities, supporting customers from product development to go-to-market planning and sales and marketing execution. It covers functional areas such as sales, marketing, clinical research and product development, strategy, talent acquisition, and physician network management. The company serves biopharmaceutical and medical device companies, healthcare information technology companies, healthcare providers, and other diversified companies including staffing and commercial real estate firms, financial institutions, and marketing and advertising agencies. Founded in 2011, it is headquartered in Framingham, Massachusetts.

Country
Price · split & dividend adjusted
News & notes moving DH
DH

Definitive Healthcare Receives Going-Private Proposal from Advent International

The special committee of Definitive Healthcare's board has confirmed receipt of a non-binding proposal from Advent International to acquire all outstanding shares of Class A common stock and Definitive OpCo Units not already owned by Advent or founder Jason Krantz, for $1.02 per share in cash. The special committee, composed of independent directors, will review the proposal with its advisors to determine the best course for the company and its stockholders. No action is required from stockholders at this time, and there is no assurance that a transaction will be pursued or completed. Rothschild & Co and Skadden, Arps are advising the special committee, while Evercore and Hogan Lovells Cadwalader are advising the company.
GlobeNewswire·16dRead more →
DH

Definitive Healthcare surges on Advent International buyout offer

Definitive Healthcare shares rose 14% in premarket trading after private equity firm Advent International made a non-binding offer to acquire the company for $1.02 per share in an all-share deal. Advent, which already owns 62.5 million Class A shares representing nearly a 59% stake, values the SaaS provider at a 36% premium to its 60-day volume-weighted average price of $0.75 per share as of August 31. The transaction, not subject to financing conditions, will see founder and executive chairman Jason Krantz roll his equity into the new entity. Concurrently, Definitive Healthcare announced Clay Ritchey, former CEO of Verato, will become its next chief executive and board member effective September 8, succeeding Kevin Coop, who departed on August 31 after more than two years.
Seeking Alpha·16dRead more →
DH

Definitive Healthcare Names Clay Ritchey as New CEO

Definitive Healthcare Corp., a leader in healthcare market data and analytics, has appointed Clay Ritchey as its next Chief Executive Officer and a member of the Board of Directors, effective September 8, 2026. Ritchey, who brings over 25 years of healthcare expertise, succeeds Kevin Coop, who departed as CEO and board member on August 31, 2026, after serving since June 2024. Ritchey joins from Verato, a healthcare master data management company, where he was CEO, and has held senior roles at Evariant, Imprivata, Equinox Healthcare, Hill-Rom, and Kronos. Chairman Jason Krantz praised Ritchey's track record of driving profitable growth and his conviction that AI will reshape healthcare, positioning Definitive Healthcare as a leader in commercial intelligence. Ritchey expressed excitement about accelerating the company's return to growth, citing its proprietary datasets and upcoming AI-powered platform.
GlobeNewswire·16dRead more →
Artificial Intelligence

Definitive Healthcare targets $220M-$222M 2026 revenue while planning Turbo general availability before year-end

Definitive Healthcare reported second-quarter 2026 revenue of $55.2 million, down 9% year-over-year, and adjusted EBITDA of $14.6 million, a 26% margin. The company launched Turbo, its new AI-powered healthcare intelligence platform, and is targeting general availability before the end of the year. For the full year 2026, management expects revenue of $220 million to $222 million and adjusted EBITDA of $57 million to $59 million, with no material revenue contribution from Turbo assumed in the guidance. The life sciences segment has been slower to respond, and the outlook for professional services has weakened due to lighter bookings in traditional analytics engagements.
Seeking Alpha·39dRead more →